City Says Prescription Misuse Caused Death of Detective Who Worked at…
The News Review:
- City Says Prescription Misuse Caused Death of Detective Who Worked at…
- AI Medical says US FDA asks co to conduct study of BAMF Spine…
- Bankruptcy underscores squeeze on some area medical practices
- BRIEF: Power Medical shares begin trading today.
- Development eyed for medical campus
City Says Prescription Misuse Caused Death of Detective Who Worked at…
New York Times – Oct 26, 2007
Detective Zadroga’s parents revealed the medical examiner’s opinion yesterday several days after he had sent a letter to them stating “with certainty beyond doubt” that their son had not died as a result of inhaling dust during the more than 400 hours he worked at ground zero. After reviewing medical evidence Charles S. Hirsch the city’s chief medical examiner concluded that Detective Zadroga had crushed pills and made them into a solution that was injected intravenously into his bloodstream. Traces of nonsoluble fillers or binders in the pills accumulated in his lungs leading to respiratory illness that caused his death in January 2006 at the age of 34 according to the medical examiner’s office… Detective Zadroga’s parents revealed the medical examiner’s opinion yesterday several days after he had sent a letter to them stating “with certainty beyond doubt” that their son had not died as a result of inhaling dust during the more than 400 hours he worked at ground zero. After reviewing medical evidence Charles S. Hirsch the city’s chief medical examiner concluded that Detective Zadroga had crushed pills and made them into a solution that was injected intravenously into his bloodstream. Traces of nonsoluble fillers or binders in the pills accumulated in his lungs leading to respiratory illness that caused his death in January 2006 at the age of 34 according to the medical examiner’s office. Ellen Borakove a spokeswoman for the medical examiner’s office said the material in Detective Zadroga’s lungs had passed through his bloodstream.
AI Medical says US FDA asks co to conduct study of BAMF Spine…
Forbes – Oct 26, 2007
The medical device company said it is currently negotiating the full details of the content and timing of the study. The study will be designed to support substantial equivalence of the BAMF Spine technology and the endpoints will include successful deployment and cement delivery as well as clinical outcome measures. The company said it expects the commercial launch of BAMF Spine product in the US in the second half of 2008.
Bankruptcy underscores squeeze on some area medical practices
Bizjournals.com – Oct 26, 2007
filed for Chapter 7 bankruptcy liquidation ct. 16 listing no assets and debts of $720000.
BRIEF: Power Medical shares begin trading today.
Free with registration – Philadelphia Inquirer – AccessMyLibrary.com – Oct 26, 2007
(26-CT-07) Philadelphia Inquirer (Philadelphia PA). 26–Shares in surgical instrument maker Power Medical Interventions Inc. of Langhorne began trading today on the Nasdaq Global Market. The initial public offering of 3. 85 million shares was.
Development eyed for medical campus
Bizjournals.com – Oct 26, 2007
The project marks an unofficial expansion of the still-emerging medical campus as it brings new investment to Main Street. To date the bulk of the expansion has taken place along High Ellicott and Washington streets. "It takes Main Street one step further" said Christopher Dirr Savarino Cos. vice president of development.
Written by admin on October 26th, 2007 with
no comments.
Read more articles on News.